Gain Therapeutics (GANX) Non-Current Deffered Revenue (2023 - 2024)
Gain Therapeutics (GANX) posted quarterly Non-Current Deffered Revenue of $47441.0 for Q4 2024, down 49.95% year-over-year from $94786.0 in Q1 2024, and down 27.98% quarter-over-quarter from $65869.0 in Q3 2024.
Gain Therapeutics (GANX) Non-Current Deffered Revenue (2023 - 2024) Analysis & Trends
Gain Therapeutics' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $47441.0 for Q4 2024.
- In Q4 2024, Non-Current Deffered Revenue fell 49.95% year-over-year to $47441.0; the TTM figure through Dec 2024 stood at $47441.0 (down 49.95% YoY), while the FY2024 annual figure was $47441.0, down 49.95% from the prior year.
- Non-Current Deffered Revenue for Q4 2024 stood at $47441.0, down from $65869.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $608982.0 in Q2 2023, with the low at $47441.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 47,441.00 |
| Sep 30, 2024 | 65,869.00 |
| Jun 30, 2024 | 80,364.00 |
| Mar 31, 2024 | 64,300.00 |
| Dec 31, 2023 | 94,786.00 |
| Sep 30, 2023 | 144,339.00 |
| Jun 30, 2023 | 608,982.00 |